AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Semler Scientific, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Credo Technology Group Holding Ltd (NASDAQ: CRDO) has received a Form 144 filing indicating a planned disposition of 80,000 common shares.

Key details are as follows:

  • Filer/Account holder: Walden Technology Ventures II LP (address in Grand Cayman).
  • Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
  • Class: Common stock.
  • Approximate sale date: 24 Jun 2025, on the NASDAQ exchange.
  • Aggregate market value of planned sale: US$7,261,816, implying an indicative price of about US$90.77 per share.
  • Shares outstanding: 169,801,216, so the planned sale equals roughly 0.05 % of CRDO’s total shares.

The filing also discloses that the shares were originally acquired directly from the issuer on 8 Dec 2017 (58,770 shares) and 22 Dec 2020 (21,230 shares) for cash consideration.

Recent trading activity: Over the last three months Walden Technology Ventures II LP has already sold 404,297 CRDO shares in five transactions, generating cumulative gross proceeds of roughly US$31.5 million. The largest single sale was 171,473 shares on 16 Jun 2025.

Because Rule 144 notices are intent to sell filings, the shares may or may not ultimately be sold, and no pricing information beyond the aggregate value is provided. The proposed volume is small relative to CRDO’s float, suggesting limited direct market impact, but continuing distributions by a venture-capital holder may be noteworthy to investors monitoring insider supply dynamics.

Credo Technology Group Holding Ltd (NASDAQ: CRDO) ha presentato un modulo 144 che segnala una pianificata cessione di 80.000 azioni ordinarie.

I dettagli principali sono i seguenti:

  • Dichiarante/Titolare del conto: Walden Technology Ventures II LP (indirizzo a Grand Cayman).
  • Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
  • Classe: Azioni ordinarie.
  • Data approssimativa di vendita: 24 giugno 2025, sul mercato NASDAQ.
  • Valore di mercato complessivo della vendita pianificata: 7.261.816 USD, che implica un prezzo indicativo di circa 90,77 USD per azione.
  • Azioni in circolazione: 169.801.216, quindi la vendita pianificata corrisponde a circa il 0,05% del totale delle azioni CRDO.

La dichiarazione rivela inoltre che le azioni sono state acquistate originariamente direttamente dall’emittente il 8 dicembre 2017 (58.770 azioni) e il 22 dicembre 2020 (21.230 azioni) mediante pagamento in contanti.

Attività recente di trading: Negli ultimi tre mesi Walden Technology Ventures II LP ha già venduto 404.297 azioni CRDO in cinque transazioni, generando proventi lordi cumulativi di circa 31,5 milioni di USD. La vendita singola più consistente è stata di 171.473 azioni il 16 giugno 2025.

Poiché le notifiche ai sensi della Regola 144 sono dichiarazioni di intenzione di vendita, le azioni potrebbero non essere effettivamente vendute, e non sono fornite informazioni sui prezzi oltre al valore complessivo. Il volume proposto è contenuto rispetto al flottante di CRDO, suggerendo un impatto diretto limitato sul mercato, ma le continue distribuzioni da parte di un investitore di venture capital possono essere rilevanti per gli investitori che monitorano la dinamica dell’offerta interna.

Credo Technology Group Holding Ltd (NASDAQ: CRDO) ha presentado un formulario 144 que indica una disposición planificada de 80,000 acciones comunes.

Los detalles clave son los siguientes:

  • Declarante/Titular de la cuenta: Walden Technology Ventures II LP (dirección en Grand Cayman).
  • Corredor: Morgan Stanley Smith Barney LLC, Executive Financial Services, Nueva York, NY.
  • Clase: Acciones comunes.
  • Fecha aproximada de venta: 24 de junio de 2025, en la bolsa NASDAQ.
  • Valor de mercado agregado de la venta planificada: 7.261.816 USD, lo que implica un precio indicativo de aproximadamente 90,77 USD por acción.
  • Acciones en circulación: 169.801.216, por lo que la venta planificada representa aproximadamente el 0,05% del total de acciones de CRDO.

El formulario también revela que las acciones fueron adquiridas originalmente directamente del emisor el 8 de diciembre de 2017 (58.770 acciones) y el 22 de diciembre de 2020 (21.230 acciones) mediante pago en efectivo.

Actividad reciente de negociación: En los últimos tres meses, Walden Technology Ventures II LP ya ha vendido 404.297 acciones de CRDO en cinco transacciones, generando ingresos brutos acumulados de aproximadamente 31,5 millones de USD. La venta individual más grande fue de 171.473 acciones el 16 de junio de 2025.

Dado que los avisos bajo la Regla 144 son declaraciones de intención de venta, las acciones pueden o no ser vendidas finalmente, y no se proporciona información de precios más allá del valor agregado. El volumen propuesto es pequeño en relación con el flotante de CRDO, lo que sugiere un impacto directo limitado en el mercado, pero las distribuciones continuas por parte de un inversor de capital riesgo pueden ser relevantes para los inversores que monitorean la dinámica de la oferta interna.

Credo Technology Group Holding Ltd (NASDAQ: CRDO)ê°¶Ä 80,000ì£� 보통ì£� 처분 계íšì� 알리ëŠ� Form 144 ì‹ ê³ ë¥� 제출했습니다.

주요 ë‚´ìš©ì€ ë‹¤ìŒê³� 같습니다:

  • ì‹ ê³ ìž�/계좌 보유ìž�: Walden Technology Ventures II LP (그랜ë“� ì¼€ì´ë§¨ 소재).
  • 중개ì�: Morgan Stanley Smith Barney LLC, Executive Financial Services, 뉴욕, NY.
  • 종류: 보통ì£�.
  • ì˜ˆìƒ ë§¤ê°ì�: 2025ë…� 6ì›� 24ì�, NASDAQ 거래ì†�.
  • ì˜ˆìƒ ë§¤ê° ì´� 시장갶Äì¹�: 미화 7,261,816달러, 주당 ì•� 90.77달러ë¡� 추정.
  • 발행 ì£¼ì‹ ìˆ�: 169,801,216ì£�, 계íšë� 매ê°ì€ CRDO ì „ì²´ 주ì‹ì� ì•� 0.05%ì—� 해당.

ì‹ ê³ ì„œì— ë”°ë¥´ë©� 해당 주ì‹ì€ ì›ëž˜ 2017ë…� 12ì›� 8ì�(58,770ì£�)ê³� 2020ë…� 12ì›� 22ì�(21,230ì£�)ì—� 발행사로부í„� 현금 대갶Äë¡� ì§ì ‘ ì·¨ë“í•� 것입니다.

최근 거래 활ë™: ì§€ë‚� 3개월 ë™ì•ˆ Walden Technology Ventures II LPëŠ� ì´ë¯¸ 다섯 ê±´ì˜ ê±°ëž˜ì—서 404,297ì£� CRDOë¥� 매ë„하여 ì´� ì•� 3,150ë§� 달러ì� ì´ìˆ˜ìµì„ 올렸습니ë‹�. ê°¶Äìž� í� ë‹¨ì¼ ë§¤ë„ëŠ� 2025ë…� 6ì›� 16ì¼ì— 171,473주였습니ë‹�.

Rule 144 공지ëŠ� ë§¤ë„ ì˜ì‚¬ë¥� 알리ëŠ� ì‹ ê³ ì´ë¯€ë¡� 실제 ë§¤ë„ ì—¬ë¶€ëŠ� 확정ë˜ì§€ 않았으며, ì´� ê°¶Äì¹� ì™¸ì— ê°¶Äê²� ì •ë³´ëŠ� 제공ë˜ì§€ 않습니다. 제안ë� ê±°ëž˜ëŸ‰ì€ CRDO 유통 ì£¼ì‹ ìˆ˜ì— ë¹„í•´ ì ì–´ 시장ì—� 미치ëŠ� ì§ì ‘ì � ì˜í–¥ì€ 제한ì ì¼ 것으ë¡� ë³´ì´ë‚�, 벤처 ìºí”¼í„� 보유ìžì˜ ì§€ì†ì ì� ì£¼ì‹ ë¶„ë°°ëŠ� ë‚´ë¶€ìž� 공급 ë™í–¥ì� 주시하는 투ìžìžì—ê²� 주목í•� 만할 ìˆ� 있습니다.

Credo Technology Group Holding Ltd (NASDAQ : CRDO) a déposé un formulaire 144 indiquant une intention de céder 80 000 actions ordinaires.

Les détails clés sont les suivants :

  • Déclarant/Titulaire du compte : Walden Technology Ventures II LP (adresse aux îles Caïmans).
  • Intermédiaire : Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
  • Catégorie : Actions ordinaires.
  • Date approximative de vente : 24 juin 2025, sur le marché NASDAQ.
  • Valeur marchande totale de la vente prévue : 7 261 816 USD, ce qui implique un prix indicatif d'environ 90,77 USD par action.
  • Actions en circulation : 169 801 216, la vente prévue représente donc environ 0,05 % du total des actions CRDO.

Le dépôt révèle également que les actions ont été initialement acquises directement auprès de l'émetteur le 8 décembre 2017 (58 770 actions) et le 22 décembre 2020 (21 230 actions) contre paiement en espèces.

Activité récente de négociation : Au cours des trois derniers mois, Walden Technology Ventures II LP a déjà vendu 404 297 actions CRDO en cinq transactions, générant des recettes brutes cumulées d'environ 31,5 millions USD. La plus grande vente individuelle a porté sur 171 473 actions le 16 juin 2025.

Étant donné que les notifications en vertu de la règle 144 sont des déclarations d'intention de vente, les actions peuvent ou non être finalement vendues, et aucune information sur les prix au-delà de la valeur globale n'est fournie. Le volume proposé est faible par rapport au flottant de CRDO, ce qui suggère un impact direct limité sur le marché, mais des distributions continues par un investisseur en capital-risque peuvent être importantes pour les investisseurs surveillant la dynamique de l'offre des initiés.

Credo Technology Group Holding Ltd (NASDAQ: CRDO) hat eine Form-144-Meldung eingereicht, die eine geplante Veräußerung von 80.000 Stammaktien anzeigt.

Wichtige Details sind wie folgt:

  • Meldender/Kontoinhaber: Walden Technology Ventures II LP (Adresse auf Grand Cayman).
  • Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
  • Klasse: Stammaktien.
  • Ungefähres Verkaufsdatum: 24. Juni 2025 an der NASDAQ-Börse.
  • Gesamtmarktwert der geplanten Veräußerung: 7.261.816 USD, was auf einen indikativem Preis von etwa 90,77 USD pro Aktie hindeutet.
  • Ausstehende Aktien: 169.801.216, somit entspricht der geplante Verkauf etwa 0,05 % der Gesamtaktien von CRDO.

Die Meldung offenbart außerdem, dass die Aktien ursprünglich direkt vom Emittenten am 8. Dezember 2017 (58.770 Aktien) und am 22. Dezember 2020 (21.230 Aktien) gegen Barzahlung erworben wurden.

Jüngste Handelsaktivität: In den letzten drei Monaten hat Walden Technology Ventures II LP bereits 404.297 CRDO-Aktien in fünf Transaktionen verkauft und dabei kumulierte Bruttoerlöse von rund 31,5 Millionen USD erzielt. Der größte Einzelverkauf umfasste 171.473 Aktien am 16. Juni 2025.

Da Rule-144-Meldungen Verkaufsabsicht anzeigen, können die Aktien letztlich verkauft werden oder auch nicht, und es werden keine Preisinformationen über den Gesamtwert hinaus bereitgestellt. Das vorgeschlagene Volumen ist im Verhältnis zum Streubesitz von CRDO gering, was auf eine begrenzte direkte Marktwirkung hindeutet, jedoch können fortlaufende Veräußerungen durch einen Venture-Capital-Investor für Anleger, die Insider-Angebotsdynamiken beobachten, von Bedeutung sein.

Positive
  • None.
Negative
  • 80,000-share planned sale represents additional insider supply, though only ~0.05 % of shares outstanding.
  • Walden Technology Ventures II LP has already sold 404,297 shares (â‰�0.24 % of float) in the past three months, indicating a continuing disposal trend.

Insights

TL;DR: VC fund files to sell 80k CRDO shares (0.05% o/s); modest size, signals ongoing exit but limited immediate price pressure.

The Form 144 shows Walden Technology Ventures II LP intends to liquidate another 80,000 CRDO shares at an estimated US$7.26 million. Combined with 404,297 shares already sold since April, the fund will have trimmed roughly 0.29 % of shares outstanding. Such volumes are minor compared with average daily trading, so mechanical impact should be negligible. Nevertheless, steady VC distribution indicates a gradual monetisation of an early position, which some investors may interpret as routine portfolio management rather than a statement on fundamentals. No operational or earnings data accompanies the filing, so this notice has neutral fundamental relevance.

TL;DR: Continued selling by early investor adds incremental supply; size small but directionally negative for sentiment.

From a portfolio-allocation perspective, insider supply—even in small tranches—creates overhang risk. Walden’s planned 80k-share sale follows five recent disposals totalling 404k shares, suggesting a programmatic exit. Although sub-0.3 % of float, repeated notices can weigh on momentum traders who monitor insider activity. Importantly, the form confirms no material undisclosed adverse information, limiting the read-through to sentiment only. I view the event as slightly negative, yet not sufficiently large to alter valuation models or position sizing.

Credo Technology Group Holding Ltd (NASDAQ: CRDO) ha presentato un modulo 144 che segnala una pianificata cessione di 80.000 azioni ordinarie.

I dettagli principali sono i seguenti:

  • Dichiarante/Titolare del conto: Walden Technology Ventures II LP (indirizzo a Grand Cayman).
  • Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
  • Classe: Azioni ordinarie.
  • Data approssimativa di vendita: 24 giugno 2025, sul mercato NASDAQ.
  • Valore di mercato complessivo della vendita pianificata: 7.261.816 USD, che implica un prezzo indicativo di circa 90,77 USD per azione.
  • Azioni in circolazione: 169.801.216, quindi la vendita pianificata corrisponde a circa il 0,05% del totale delle azioni CRDO.

La dichiarazione rivela inoltre che le azioni sono state acquistate originariamente direttamente dall’emittente il 8 dicembre 2017 (58.770 azioni) e il 22 dicembre 2020 (21.230 azioni) mediante pagamento in contanti.

Attività recente di trading: Negli ultimi tre mesi Walden Technology Ventures II LP ha già venduto 404.297 azioni CRDO in cinque transazioni, generando proventi lordi cumulativi di circa 31,5 milioni di USD. La vendita singola più consistente è stata di 171.473 azioni il 16 giugno 2025.

Poiché le notifiche ai sensi della Regola 144 sono dichiarazioni di intenzione di vendita, le azioni potrebbero non essere effettivamente vendute, e non sono fornite informazioni sui prezzi oltre al valore complessivo. Il volume proposto è contenuto rispetto al flottante di CRDO, suggerendo un impatto diretto limitato sul mercato, ma le continue distribuzioni da parte di un investitore di venture capital possono essere rilevanti per gli investitori che monitorano la dinamica dell’offerta interna.

Credo Technology Group Holding Ltd (NASDAQ: CRDO) ha presentado un formulario 144 que indica una disposición planificada de 80,000 acciones comunes.

Los detalles clave son los siguientes:

  • Declarante/Titular de la cuenta: Walden Technology Ventures II LP (dirección en Grand Cayman).
  • Corredor: Morgan Stanley Smith Barney LLC, Executive Financial Services, Nueva York, NY.
  • Clase: Acciones comunes.
  • Fecha aproximada de venta: 24 de junio de 2025, en la bolsa NASDAQ.
  • Valor de mercado agregado de la venta planificada: 7.261.816 USD, lo que implica un precio indicativo de aproximadamente 90,77 USD por acción.
  • Acciones en circulación: 169.801.216, por lo que la venta planificada representa aproximadamente el 0,05% del total de acciones de CRDO.

El formulario también revela que las acciones fueron adquiridas originalmente directamente del emisor el 8 de diciembre de 2017 (58.770 acciones) y el 22 de diciembre de 2020 (21.230 acciones) mediante pago en efectivo.

Actividad reciente de negociación: En los últimos tres meses, Walden Technology Ventures II LP ya ha vendido 404.297 acciones de CRDO en cinco transacciones, generando ingresos brutos acumulados de aproximadamente 31,5 millones de USD. La venta individual más grande fue de 171.473 acciones el 16 de junio de 2025.

Dado que los avisos bajo la Regla 144 son declaraciones de intención de venta, las acciones pueden o no ser vendidas finalmente, y no se proporciona información de precios más allá del valor agregado. El volumen propuesto es pequeño en relación con el flotante de CRDO, lo que sugiere un impacto directo limitado en el mercado, pero las distribuciones continuas por parte de un inversor de capital riesgo pueden ser relevantes para los inversores que monitorean la dinámica de la oferta interna.

Credo Technology Group Holding Ltd (NASDAQ: CRDO)ê°¶Ä 80,000ì£� 보통ì£� 처분 계íšì� 알리ëŠ� Form 144 ì‹ ê³ ë¥� 제출했습니다.

주요 ë‚´ìš©ì€ ë‹¤ìŒê³� 같습니다:

  • ì‹ ê³ ìž�/계좌 보유ìž�: Walden Technology Ventures II LP (그랜ë“� ì¼€ì´ë§¨ 소재).
  • 중개ì�: Morgan Stanley Smith Barney LLC, Executive Financial Services, 뉴욕, NY.
  • 종류: 보통ì£�.
  • ì˜ˆìƒ ë§¤ê°ì�: 2025ë…� 6ì›� 24ì�, NASDAQ 거래ì†�.
  • ì˜ˆìƒ ë§¤ê° ì´� 시장갶Äì¹�: 미화 7,261,816달러, 주당 ì•� 90.77달러ë¡� 추정.
  • 발행 ì£¼ì‹ ìˆ�: 169,801,216ì£�, 계íšë� 매ê°ì€ CRDO ì „ì²´ 주ì‹ì� ì•� 0.05%ì—� 해당.

ì‹ ê³ ì„œì— ë”°ë¥´ë©� 해당 주ì‹ì€ ì›ëž˜ 2017ë…� 12ì›� 8ì�(58,770ì£�)ê³� 2020ë…� 12ì›� 22ì�(21,230ì£�)ì—� 발행사로부í„� 현금 대갶Äë¡� ì§ì ‘ ì·¨ë“í•� 것입니다.

최근 거래 활ë™: ì§€ë‚� 3개월 ë™ì•ˆ Walden Technology Ventures II LPëŠ� ì´ë¯¸ 다섯 ê±´ì˜ ê±°ëž˜ì—서 404,297ì£� CRDOë¥� 매ë„하여 ì´� ì•� 3,150ë§� 달러ì� ì´ìˆ˜ìµì„ 올렸습니ë‹�. ê°¶Äìž� í� ë‹¨ì¼ ë§¤ë„ëŠ� 2025ë…� 6ì›� 16ì¼ì— 171,473주였습니ë‹�.

Rule 144 공지ëŠ� ë§¤ë„ ì˜ì‚¬ë¥� 알리ëŠ� ì‹ ê³ ì´ë¯€ë¡� 실제 ë§¤ë„ ì—¬ë¶€ëŠ� 확정ë˜ì§€ 않았으며, ì´� ê°¶Äì¹� ì™¸ì— ê°¶Äê²� ì •ë³´ëŠ� 제공ë˜ì§€ 않습니다. 제안ë� ê±°ëž˜ëŸ‰ì€ CRDO 유통 ì£¼ì‹ ìˆ˜ì— ë¹„í•´ ì ì–´ 시장ì—� 미치ëŠ� ì§ì ‘ì � ì˜í–¥ì€ 제한ì ì¼ 것으ë¡� ë³´ì´ë‚�, 벤처 ìºí”¼í„� 보유ìžì˜ ì§€ì†ì ì� ì£¼ì‹ ë¶„ë°°ëŠ� ë‚´ë¶€ìž� 공급 ë™í–¥ì� 주시하는 투ìžìžì—ê²� 주목í•� 만할 ìˆ� 있습니다.

Credo Technology Group Holding Ltd (NASDAQ : CRDO) a déposé un formulaire 144 indiquant une intention de céder 80 000 actions ordinaires.

Les détails clés sont les suivants :

  • Déclarant/Titulaire du compte : Walden Technology Ventures II LP (adresse aux îles Caïmans).
  • Intermédiaire : Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
  • Catégorie : Actions ordinaires.
  • Date approximative de vente : 24 juin 2025, sur le marché NASDAQ.
  • Valeur marchande totale de la vente prévue : 7 261 816 USD, ce qui implique un prix indicatif d'environ 90,77 USD par action.
  • Actions en circulation : 169 801 216, la vente prévue représente donc environ 0,05 % du total des actions CRDO.

Le dépôt révèle également que les actions ont été initialement acquises directement auprès de l'émetteur le 8 décembre 2017 (58 770 actions) et le 22 décembre 2020 (21 230 actions) contre paiement en espèces.

Activité récente de négociation : Au cours des trois derniers mois, Walden Technology Ventures II LP a déjà vendu 404 297 actions CRDO en cinq transactions, générant des recettes brutes cumulées d'environ 31,5 millions USD. La plus grande vente individuelle a porté sur 171 473 actions le 16 juin 2025.

Étant donné que les notifications en vertu de la règle 144 sont des déclarations d'intention de vente, les actions peuvent ou non être finalement vendues, et aucune information sur les prix au-delà de la valeur globale n'est fournie. Le volume proposé est faible par rapport au flottant de CRDO, ce qui suggère un impact direct limité sur le marché, mais des distributions continues par un investisseur en capital-risque peuvent être importantes pour les investisseurs surveillant la dynamique de l'offre des initiés.

Credo Technology Group Holding Ltd (NASDAQ: CRDO) hat eine Form-144-Meldung eingereicht, die eine geplante Veräußerung von 80.000 Stammaktien anzeigt.

Wichtige Details sind wie folgt:

  • Meldender/Kontoinhaber: Walden Technology Ventures II LP (Adresse auf Grand Cayman).
  • Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, NY.
  • Klasse: Stammaktien.
  • Ungefähres Verkaufsdatum: 24. Juni 2025 an der NASDAQ-Börse.
  • Gesamtmarktwert der geplanten Veräußerung: 7.261.816 USD, was auf einen indikativem Preis von etwa 90,77 USD pro Aktie hindeutet.
  • Ausstehende Aktien: 169.801.216, somit entspricht der geplante Verkauf etwa 0,05 % der Gesamtaktien von CRDO.

Die Meldung offenbart außerdem, dass die Aktien ursprünglich direkt vom Emittenten am 8. Dezember 2017 (58.770 Aktien) und am 22. Dezember 2020 (21.230 Aktien) gegen Barzahlung erworben wurden.

Jüngste Handelsaktivität: In den letzten drei Monaten hat Walden Technology Ventures II LP bereits 404.297 CRDO-Aktien in fünf Transaktionen verkauft und dabei kumulierte Bruttoerlöse von rund 31,5 Millionen USD erzielt. Der größte Einzelverkauf umfasste 171.473 Aktien am 16. Juni 2025.

Da Rule-144-Meldungen Verkaufsabsicht anzeigen, können die Aktien letztlich verkauft werden oder auch nicht, und es werden keine Preisinformationen über den Gesamtwert hinaus bereitgestellt. Das vorgeschlagene Volumen ist im Verhältnis zum Streubesitz von CRDO gering, was auf eine begrenzte direkte Marktwirkung hindeutet, jedoch können fortlaufende Veräußerungen durch einen Venture-Capital-Investor für Anleger, die Insider-Angebotsdynamiken beobachten, von Bedeutung sein.

false 0001554859 0001554859 2025-06-24 2025-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 24, 2025

 

 

 

SEMLER SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36305   26-1367393
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

51 E Campbell Ave, Suite 107-D
Campbell, CA
  95008
(Address of principal executive offices)   (Zip Code)

 

Registrant's telephone number, including area code: (877) 774-4211

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange on which registered

Common Stock, $0.001 par value per share

  SMLR  

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company                  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         ¨

 

 

 

 

Item 8.01. Other Events.

 

On June 24, 2025, Semler Scientific, Inc. (Semler Scientific), announced the formation of a wholly-owned subsidiary, CardioVanta, Inc., that will comprise its future healthcare business activities focused on early detection of heart failure and cardiac arrythmia monitoring and will seek capital from outside investors to validate its long-term value and fund its relatively modest initial capital needs.

 

Forward-Looking Statements

 

This current report contains “forward-looking” statements. Such statements can be identified by, among other things, the use of forward-looking language such as the words “believe,” “goal,” “may,” “will,” “intend,” “expect,” “anticipate,” “estimate,” “project,” “would,” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions. The forward-looking statements in this current report include express or implied statements regarding CardioVanta’s future business activities and value; obtaining investment in CardioVanta and its capital needs; acquiring and holding Bitcoin; sales of securities under equity offerings and other financings to support additional Bitcoin purchases; and its cash flows from operations, among others. Such forward-looking statements are subject to a number of risks and uncertainties that could cause Semler Scientific’s actual results to differ materially from those discussed here, such as risks inherent with obtaining FDA clearance for additional indications; conducting certain healthcare operations through CardioVanta and bringing in new investors; investing in Bitcoin, including Bitcoin's volatility; risk of implementing a Bitcoin treasury strategy; risks related to raising capital and generating sufficient cash to acquire Bitcoin; risks related to Semler Scientific’s indebtedness, and risks related to Semler Scientific’s proposed settlement with the Department of Justice; along with those other risk factors detailed in Semler Scientific's filings with the Securities and Exchange Commission. These forward-looking statements involve assumptions, estimates, and uncertainties that reflect current internal projections, expectations or beliefs. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. All forward-looking statements contained in this current report are qualified in their entirety by these cautionary statements and the risk factors described above. Furthermore, all such statements are made as of the date of this current report and Semler Scientific assumes no obligation to update or revise these statements unless otherwise required by law.

 

No Offer or Solicitation

 

This current report does not and shall not constitute an offer to sell or a solicitation of an offer to buy any securities of Semler Scientific, Inc. or CardioVanta, Inc., nor shall there be any offer, solicitation or sale of such securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SEMLER SCIENTIFIC, INC.
     
Date: June 24, 2025 By: /s/ Renae Cormier
    Name: Renae Cormier
    Title: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

 

 

 

 

FAQ

How many CRDO shares are covered by the latest Form 144 filing?

The notice covers 80,000 common shares of Credo Technology Group Holding Ltd.

What is the aggregate market value of the proposed CRDO share sale?

The filing lists an aggregate market value of US$7,261,816 for the 80,000 shares.

Which broker will execute the CRDO share sale under this Form 144?

Morgan Stanley Smith Barney LLC, Executive Financial Services, is named as the broker.

What percentage of Credo Technology’s outstanding shares does 80,000 shares represent?

The planned sale equals approximately 0.05 % of the 169,801,216 shares outstanding.

How many CRDO shares has Walden Technology Ventures II LP sold in the last three months?

The fund sold 404,297 common shares in five transactions between 5 Jun 2025 and 18 Jun 2025.

When were the shares to be sold originally acquired?

58,770 shares were acquired on 8 Dec 2017 and 21,230 shares on 22 Dec 2020, both directly from the issuer for cash.
Semler Scientific Inc

NASDAQ:SMLR

SMLR Rankings

SMLR Latest News

SMLR Latest SEC Filings

SMLR Stock Data

639.47M
12.02M
18.39%
61.37%
17.11%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
United States
CAMPBELL